Radio(chemo)therapy in anal cancer: evaluation of sex-specific disparities across AJCC stages.

IF 2.7 3区 医学 Q3 ONCOLOGY
F Fuchs, P Rogowski, M Rottler, M A Shouman, K Heinrich, F Kühn, C Belka, K Unger, F Walter
{"title":"Radio(chemo)therapy in anal cancer: evaluation of sex-specific disparities across AJCC stages.","authors":"F Fuchs, P Rogowski, M Rottler, M A Shouman, K Heinrich, F Kühn, C Belka, K Unger, F Walter","doi":"10.1007/s00066-025-02368-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate sex differences in anal squamous cell carcinomas (ASCC), with a particular focus on the prognostic significance of the American Joint Committee on Cancer (AJCC) 9th edition staging system for oncological outcome.</p><p><strong>Methods: </strong>A retrospective analysis was conducted in 188 patients with histologically confirmed ASCC who underwent definitive (chemo)radiotherapy between 2004 and 2020. Patient- and tumor-related data were collected. Tumor stage groups were classified according to the AJCC 9th edition. Overall survival (OS), disease-free survival (DFS), freedom from recurrence (FFR), and colostomy-free survival (CFS) were analyzed using the Kaplan-Meier method for univariate testing and Cox regression models for multivariate analysis. Differences between sexes were assessed.</p><p><strong>Results: </strong>The cohort included 134 females and 54 males, with a median follow-up of 83 months. Females exhibited significantly better OS (p = 0.01), DFS (p = 0.01), and CFS (p = 0.03). For male patients, there was a clear trend towards better OS (p = 0.08), DFS (p = 0.10), and FFR (p = 0.09) in earlier tumors as well as significantly better CFS (p = 0.04). In contrast, in the female subgroup, there were no significant differences in OS (p = 0.64), DFS (p = 0.52), and CFS (p = 0.25) with respect to tumor stage. In multivariate analysis, male sex, older age, and advanced tumor stages were significant risk factors for poorer OS, DFS, and CFS.</p><p><strong>Conclusion: </strong>This study highlights significant sex differences in ASCC prognoses, with females showing better survival outcomes. The prognostic value of the AJCC 9th edition staging system differs between sexes; thus, we support the inclusion of sex as a prognostic factor in staging systems.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-025-02368-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study aimed to investigate sex differences in anal squamous cell carcinomas (ASCC), with a particular focus on the prognostic significance of the American Joint Committee on Cancer (AJCC) 9th edition staging system for oncological outcome.

Methods: A retrospective analysis was conducted in 188 patients with histologically confirmed ASCC who underwent definitive (chemo)radiotherapy between 2004 and 2020. Patient- and tumor-related data were collected. Tumor stage groups were classified according to the AJCC 9th edition. Overall survival (OS), disease-free survival (DFS), freedom from recurrence (FFR), and colostomy-free survival (CFS) were analyzed using the Kaplan-Meier method for univariate testing and Cox regression models for multivariate analysis. Differences between sexes were assessed.

Results: The cohort included 134 females and 54 males, with a median follow-up of 83 months. Females exhibited significantly better OS (p = 0.01), DFS (p = 0.01), and CFS (p = 0.03). For male patients, there was a clear trend towards better OS (p = 0.08), DFS (p = 0.10), and FFR (p = 0.09) in earlier tumors as well as significantly better CFS (p = 0.04). In contrast, in the female subgroup, there were no significant differences in OS (p = 0.64), DFS (p = 0.52), and CFS (p = 0.25) with respect to tumor stage. In multivariate analysis, male sex, older age, and advanced tumor stages were significant risk factors for poorer OS, DFS, and CFS.

Conclusion: This study highlights significant sex differences in ASCC prognoses, with females showing better survival outcomes. The prognostic value of the AJCC 9th edition staging system differs between sexes; thus, we support the inclusion of sex as a prognostic factor in staging systems.

肛门癌的放射(化疗)治疗:AJCC分期性别特异性差异的评估。
目的:本研究旨在探讨肛门鳞状细胞癌(ASCC)的性别差异,特别关注美国癌症联合委员会(AJCC)第9版分期系统对肿瘤预后的影响。方法:回顾性分析2004年至2020年间,188例经组织学证实的ASCC患者接受了最终(化疗)放疗。收集患者和肿瘤相关数据。肿瘤分期按AJCC第9版进行分类。采用Kaplan-Meier法进行单因素检验,Cox回归模型进行多因素分析,对总生存期(OS)、无病生存期(DFS)、无复发生存期(FFR)和无结肠造口生存期(CFS)进行分析。评估了两性之间的差异。结果:该队列包括134名女性和54名男性,中位随访时间为83个月。女性表现出较好的OS (p = 0.01)、DFS (p = 0.01)和CFS (p = 0.03)。对于男性患者,早期肿瘤的OS (p = 0.08)、DFS (p = 0.10)和FFR (p = 0.09)明显改善,CFS明显改善(p = 0.04)。相比之下,在女性亚组中,肿瘤分期方面,OS (p = 0.64)、DFS (p = 0.52)和CFS (p = 0.25)无显著差异。在多变量分析中,男性、年龄和肿瘤分期是较差的OS、DFS和CFS的重要危险因素。结论:本研究强调了ASCC预后的显著性别差异,女性表现出更好的生存结果。AJCC第9版分期系统的预后价值存在性别差异;因此,我们支持将性别作为分期系统的预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
12.90%
发文量
141
审稿时长
3-8 weeks
期刊介绍: Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信